Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis. - Wikidata - wikimedia - TriplyDB

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

http://www.wikidata.org/entity/Q38553845

about

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Diabetic Wounds Exhibit Decreased Ym1 and Arginase Expression with Increased Expression of IL-17 and IL-20.Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications.Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.Remission in psoriatic arthritis-where are we now?Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation.Could Sodium Chloride be an Environmental Trigger for Immune-Mediated Diseases? An Overview of the Experimental and Clinical Evidence.Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?

P2860

Q26745789-3B6C3230-892D-45C1-9360-0A19D54C1491 Q26767276-F0C6F49E-F985-406E-AF4D-9714C591F9D3 Q30248908-6648DAE9-26CD-42ED-A7AF-6411A93653CA Q36190962-CC5F639D-943E-4823-9493-30CACB499617 Q37408988-F36F660A-AC70-4521-BECC-56D5C653D16A Q39376982-11EE961C-A394-4195-AA5B-13A9431E9D5F Q47253021-1589A04E-66F1-4B38-98D4-E64A157B5E00 Q47432586-C3EE8488-4741-4F25-9E0C-3D37756E4260 Q47696280-E8AF571D-56E3-4A8B-A671-59BFA93DE79A Q47704613-6AEEB5B0-F470-4B8F-B441-AF968C3C91B7 Q48179370-944F8619-F5C6-41CD-9E87-9517D8A47790 Q54979508-0747745B-65D1-4DB1-B521-C00BA9BE1D6F Q58724084-14FA8622-E49B-4CEC-B8C2-0D7E0FB9FD4B

P2860

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

http://www.wikidata.org/entity/Q38553845

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

@en

type

label

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

@en

prefLabel

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

@en

P1433

Q38553845-F2AEB8C4-8FDB-473D-AEEF-1A7DAE45AF9C

P1476

Q38553845-947B2557-FF25-4E61-8AC4-D7C67087240C

P2093

Q38553845-C62573CF-46F2-4F1B-AA57-F496D1DAAA7F

Q38553845-E4150D2A-ACC4-40B8-BCC1-D74E73A828C7

P2860

Q38553845-0724F10B-2CF3-448C-8784-EC33C3F4FD4C

Q38553845-075385AA-3076-434A-AAF5-C92AA72ABAEF

Q38553845-095F64F9-3CCF-4C58-9443-9DD831C2A8AC

Q38553845-0D4E540F-73AA-4D08-9B03-17BE43DC89FE

Q38553845-1821601E-44C9-4EBB-B549-94D110EFD821

Q38553845-1BC3A45E-5D55-427D-BB77-915FD46F2CEA

Q38553845-200086BC-FE83-4EBB-A86A-4916B72C4DA4

Q38553845-20C84369-56B8-4DDB-AC6B-15F1C22090DC

Q38553845-24AB6782-A387-4255-8F2F-66908AB89A3A

Q38553845-2E21F601-D184-4DC9-AA4E-7A64C2AA4545

P2888

Q38553845-667322D3-3ED4-4FC4-BC15-2059E521B0D4

P304

Q38553845-35536659-7BB0-4B60-AA91-09B4D719BD95

P31

Q38553845-87A2C15F-A0F6-4A0D-B530-E166B8434F77

P356

Q38553845-0BF9A03E-0B75-4A1E-B61E-12D1C0192500

P433

Q38553845-7FF80E5A-52C1-493D-A46F-34B44B9959F9

P478

Q38553845-AF9ED028-39A8-4C73-BF5D-3C1AE532758F

P50

Q38553845-E6F2DE35-587F-49EC-919A-BF887F3B3F2F

P577

Q38553845-26BD2386-9079-454D-B1CD-A111099E17C0

P6179

Q38553845-F3C6B327-ABCF-4D34-B9AB-4249F22B73C1

P698

Q38553845-FD49FF56-9986-4DA2-9796-CD6F7A0371D0

P356

S11926-015-0529-9

P1433

Current Rheumatology Reports

P1476

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

@en

P2093

B W Kirkham

http://www.w3.org/2001/XMLSchema#string

L E Durham

http://www.w3.org/2001/XMLSchema#string

P2860

IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

Molecular characterization of the human interleukin (IL)-17 receptor

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo

Fate mapping of IL-17-producing T cells in inflammatory responses

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven

Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death

P2888

s11926-015-0529-9

P304

55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-015-0529-9

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Leonie S. Taams

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036296892

http://www.w3.org/2001/XMLSchema#string

P698

26209291

http://www.w3.org/2001/XMLSchema#string